BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25877757)

  • 1. Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients.
    Dong H; Bao D; Guo X; Hu J; Li X; Wan S; Xing J
    Tumour Biol; 2015 Sep; 36(9):7151-7. PubMed ID: 25877757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase gene polymorphisms as important contributors affecting hepatocellular carcinoma prognosis.
    Wang X; Sun X; Du X; Zhou F; Yang F; Xing J; Dong G; Guo X
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):319-326. PubMed ID: 28043790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer.
    Guo X; Li D; Wu Y; Chen Y; Zhou X; Wang X; Huang X; Li X; Yang H; Xing J
    Lung Cancer; 2015 Feb; 87(2):162-8. PubMed ID: 25576295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Lima A; Seabra V; Martins S; Coelho A; Araújo A; Medeiros R
    Mol Biol Rep; 2014 May; 41(5):3349-57. PubMed ID: 24554028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
    Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S
    Clin Transl Oncol; 2016 Jan; 18(1):107-12. PubMed ID: 26220094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC.
    Cui LH; Yu Z; Zhang TT; Shin MH; Kim HN; Choi JS
    Pharmacogenomics; 2011 Jun; 12(6):797-808. PubMed ID: 21605004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
    Chamizo C; Zazo S; Dómine M; Cristóbal I; García-Foncillas J; Rojo F; Madoz-Gúrpide J
    BMC Pulm Med; 2015 Oct; 15():132. PubMed ID: 26502926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
    Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A
    Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-related single-nucleotide polymorphism of XPO5 is strongly correlated with the prognosis and chemotherapy response in advanced non-small-cell lung cancer patients.
    Geng JQ; Wang XC; Li LF; Zhao J; Wu S; Yu GP; Zhu KJ
    Tumour Biol; 2016 Feb; 37(2):2257-65. PubMed ID: 26358254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.
    Wang X; Wang Y; Wang Y; Cheng J; Wang Y; Ha M
    J Biomed Sci; 2013 Jan; 20(1):5. PubMed ID: 23350714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
    Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J
    Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer.
    Takehara A; Kawakami K; Ohta N; Oyama K; Ota Y; Oda M; Watanabe G
    Anticancer Res; 2005; 25(6C):4455-61. PubMed ID: 16334126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
    Li P; Wang YD; Cheng J; Chen JC; Ha MW
    Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variations in SLC3A2/CD98 gene as prognosis predictors in non-small cell lung cancer.
    Guo X; Li H; Fei F; Liu B; Li X; Yang H; Chen Z; Xing J
    Mol Carcinog; 2015 Jun; 54 Suppl 1():E52-60. PubMed ID: 24782339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer.
    Glubb DM; Paré-Brunet L; Jantus-Lewintre E; Jiang C; Crona D; Etheridge AS; Mirza O; Zhang W; Seiser EL; Rzyman W; Jassem J; Auman T; Hirsch FR; Owzar K; Camps C; Dziadziuszko R; Innocenti F
    J Thorac Oncol; 2015 Jul; 10(7):1067-75. PubMed ID: 26134224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variants in
    He Y; Wang G; Wang Q; Zhao Z; Gan L; Yang S; Wang Y; Guo S; An J; Zhang J; Zhang Z; Zhou F
    Future Oncol; 2021 Mar; 17(7):795-805. PubMed ID: 33541123
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
    Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
    Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.